ViCentra triples insulin pump manufacturing capacity to 17,000 users, positioning for European market expansion and U.S. entry.

Leica Biosystems and CellCarta expand companion diagnostic development globally using a parallel-execution model built and tested in China.

BXCL501 reduces agitation across severity levels in at-home trial, with strongest effects in severe cases ahead of FDA decision.

Zenas BioPharma files FDA application for obexelimab in IgG4-Related Disease, showing 56% flare risk reduction in Phase 3 trials.

Medtronic trades at 21.2x earnings while sitting on 170+ active trials and a balance sheet built for deals. The...

Pacira BioSciences faces proxy fight over board seats at June meeting as activist pushes for change amid valuation concerns.

BioXcel IGALMI shows efficacy in at-home agitation trial data across all severity levels, with largest effect in severe episodes...

Zenas BioPharma files BLA for obexelimab in IgG4-Related Disease following Phase 3 results showing 56% reduction in flare risk.

Pfizer partners with Innovent Biologics on 12 oncology programs in $10.5B deal, focusing on ADCs and multispecific antibodies.

Blackstone commits $1.3B to Apogee's zumilokibart in largest pre-Phase 3 royalty deal, providing non-dilutive financing through commercialization.